Matches in Wikidata for { <http://www.wikidata.org/entity/Q66389562> ?p ?o ?g. }
Showing items 1 to 49 of
49
with 100 items per page.
- Q66389562 description "clinical trial" @default.
- Q66389562 description "ensayu clínicu" @default.
- Q66389562 description "klinisch onderzoek" @default.
- Q66389562 description "клінічне випробування" @default.
- Q66389562 name "A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)" @default.
- Q66389562 name "A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer" @default.
- Q66389562 type Item @default.
- Q66389562 label "A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)" @default.
- Q66389562 label "A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer" @default.
- Q66389562 prefLabel "A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)" @default.
- Q66389562 prefLabel "A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer" @default.
- Q66389562 P1132 Q66389562-6D67380C-6A23-48F1-B13F-C305D8B2F99C @default.
- Q66389562 P1476 Q66389562-2E1AC80B-9572-4329-8840-0C2229C302CC @default.
- Q66389562 P17 Q66389562-0D738352-EFB3-4B65-B14F-29FA3022647B @default.
- Q66389562 P17 Q66389562-635A9500-C907-4B01-97BC-49B1C57939E8 @default.
- Q66389562 P17 Q66389562-DDC3D919-D64A-4485-83EC-478B21856980 @default.
- Q66389562 P17 Q66389562-FFC7810B-1238-4E29-A8AD-AA800FC72E17 @default.
- Q66389562 P1813 Q66389562-19018B44-75F5-4D07-9874-AB7BE2CAE6CD @default.
- Q66389562 P2899 Q66389562-D9C4BB3C-0612-40FD-B67A-691BBDDDADE3 @default.
- Q66389562 P3098 Q66389562-F7B4B3F5-4543-498F-BCE8-911979BB71F6 @default.
- Q66389562 P31 Q66389562-588AA474-F5F5-4CDA-AE3A-2974A06FC0CB @default.
- Q66389562 P4135 Q66389562-C8FDE6F2-9AE2-4C8A-83A8-204D6D51FC21 @default.
- Q66389562 P4844 Q66389562-23B4114C-DE48-4067-86E4-D721496680A0 @default.
- Q66389562 P4844 Q66389562-76B2C2E6-B9BC-460A-89AA-48FA1EAE6F35 @default.
- Q66389562 P4844 Q66389562-83C42F1B-DFB6-413B-B4EB-DC22623B9FA0 @default.
- Q66389562 P4844 Q66389562-E082A787-B7DE-45CF-87E6-DB96EEBE0302 @default.
- Q66389562 P580 Q66389562-10AEF5F0-0F49-4314-A94F-51E870870EA1 @default.
- Q66389562 P582 Q66389562-9844BAAC-AA9A-4DAF-97F4-60A3D6C02D03 @default.
- Q66389562 P6099 Q66389562-D823C046-27D4-46D6-B741-BA8C329F0B31 @default.
- Q66389562 P8363 Q66389562-D6110DB2-41F0-40FB-8CDD-B9EB309D22AD @default.
- Q66389562 P1132 "+586" @default.
- Q66389562 P1476 "A Phase III, Open-label, Randomized Study of Osimertinib With or Without Platinum Plus Pemetrexed Chemotherapy, as First-line Treatment in Patients With Epidermal Growth Factor Receptor (EGFR) Mutation Positive, Locally Advanced Non-Small Cell Lung Cancer (FLAURA2)" @default.
- Q66389562 P17 Q16 @default.
- Q66389562 P17 Q17 @default.
- Q66389562 P17 Q408 @default.
- Q66389562 P17 Q865 @default.
- Q66389562 P1813 "FLAURA2" @default.
- Q66389562 P2899 "+18" @default.
- Q66389562 P3098 "NCT04035486" @default.
- Q66389562 P31 Q30612 @default.
- Q66389562 P4135 "+110" @default.
- Q66389562 P4844 Q21506464 @default.
- Q66389562 P4844 Q412415 @default.
- Q66389562 P4844 Q415220 @default.
- Q66389562 P4844 Q415588 @default.
- Q66389562 P580 "2019-07-02T00:00:00Z" @default.
- Q66389562 P582 "2023-03-21T00:00:00Z" @default.
- Q66389562 P6099 Q42824827 @default.
- Q66389562 P8363 Q78089383 @default.